C4 Therapeutics, Inc. Marketable Securities (Non-Current)
C4 Therapeutics, Inc. (CCCC) had Marketable Securities (Non-Current) of $52.36 million as of 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Balance Sheet › Assets › Long-Term Investments
us-gaap:MarketableSecuritiesNoncurrent · last filed 2022-11-03
- 2022-09-30: Marketable Securities, Noncurrent $52.36M.
- 2022-06-30: Marketable Securities, Noncurrent $90.06M.
- 2022-03-31: Marketable Securities, Noncurrent $130.48M.
- 2021-12-31: Marketable Securities, Noncurrent $142.20M.
| Period end | Marketable Securities, Noncurrent |
|---|---|
| 2022-09-30 | $52.36M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $90.06M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $130.48M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $142.20M 10-Q · filed 2022-11-03 |
| 2021-09-30 | $78.19M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $32.77M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $32.49M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |